182
Participants
Start Date
May 31, 2004
Primary Completion Date
August 31, 2005
Study Completion Date
August 31, 2005
exenatide
After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \[5 μg\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \[10 μg\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
Placebo
After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
Research Site, Birmingham
Research Site, La Jolla
Research Site, San Mateo
Research Site, Santa Barbara
Research Site, Spring Valley
Research Site, Hialeah
Research Site, Jacksonville
Research Site, Melbourne
Research Site, West Palm Beach
Research Site, Atlanta
Research Site, Honolulu
Research Site, Idaho Falls
Research Site, Chicago
Research Site, Baton Rouge
Research Site, Kalamazoo
Research Site, Troy
Research Site, Butte
Research Site, McCook
Research Site, North Platte
Research Site, Omaha
Research Site, Scottsbluff
Research Site, Princeton
Research Site, Albuquerque
Research Site, Albany
Research Site, New York
Research Site, Rochester
Research Site, Greenville
Research Site, Cleveland
Research Site, Greenville
Research Site, Chattanooga
Research Site, Knoxville
Research Site, Dallas
Research Site, Georgetown
Research Site, San Antonio
Research Site, The Colony
Research Site, Olympia
Research Site, Renton
Research Site, Tacoma
Research Site, Charleston
Research Site, Huntington
Research Site, Calgary
Research Site, Vancouver
Research Site, Dartmouth
Research Site, London
Research Site, Toronto
Research Site, Montreal
Research Site, Granada
Research Site, Seville
Research Site, Valencia
Research Site, Valladolid
Research Site, Zaragoza
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY